325 related articles for article (PubMed ID: 20419280)
1. New therapeutic targets for mood disorders.
Machado-Vieira R; Salvadore G; DiazGranados N; Ibrahim L; Latov D; Wheeler-Castillo C; Baumann J; Henter ID; Zarate CA
ScientificWorldJournal; 2010 Apr; 10():713-26. PubMed ID: 20419280
[TBL] [Abstract][Full Text] [Related]
2. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
3. The role of NMDA receptors in the pathophysiology and treatment of mood disorders.
Ghasemi M; Phillips C; Trillo L; De Miguel Z; Das D; Salehi A
Neurosci Biobehav Rev; 2014 Nov; 47():336-58. PubMed ID: 25218759
[TBL] [Abstract][Full Text] [Related]
4. Potential novel therapeutics for bipolar disorders.
Machado-Vieira R; Manji HK; Zarate CA
Curr Top Behav Neurosci; 2011; 5():303-29. PubMed ID: 25236562
[TBL] [Abstract][Full Text] [Related]
5. Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.
Machado-Vieira R; Zarate CA
Depress Anxiety; 2011 Apr; 28(4):267-81. PubMed ID: 21456037
[TBL] [Abstract][Full Text] [Related]
6. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.
Rybakowski JK
CNS Drugs; 2013 Mar; 27(3):165-73. PubMed ID: 23378337
[TBL] [Abstract][Full Text] [Related]
7. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
8. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers.
Gould TD; Quiroz JA; Singh J; Zarate CA; Manji HK
Mol Psychiatry; 2004 Aug; 9(8):734-55. PubMed ID: 15136794
[TBL] [Abstract][Full Text] [Related]
9. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment.
Pandey GN; Ren X; Rizavi HS; Dwivedi Y
J Psychiatr Res; 2010 Feb; 44(3):143-8. PubMed ID: 19717166
[TBL] [Abstract][Full Text] [Related]
11. Novel glutamatergic agents for major depressive disorder and bipolar disorder.
Machado-Vieira R; Ibrahim L; Henter ID; Zarate CA
Pharmacol Biochem Behav; 2012 Feb; 100(4):678-87. PubMed ID: 21971560
[TBL] [Abstract][Full Text] [Related]
12. Novel routes to bipolar disorder drug discovery.
Hoertel N; de Maricourt P; Gorwood P
Expert Opin Drug Discov; 2013 Aug; 8(8):907-18. PubMed ID: 23706065
[TBL] [Abstract][Full Text] [Related]
13. Drugs for depression and bipolar disorder.
Treat Guidel Med Lett; 2010 May; 8(93):35-42. PubMed ID: 20414177
[No Abstract] [Full Text] [Related]
14. Epigenetic Drugs for Mood Disorders.
Peedicayil J; Kumar A
Prog Mol Biol Transl Sci; 2018; 157():151-174. PubMed ID: 29933949
[TBL] [Abstract][Full Text] [Related]
15. Glutamatergic modulators: the future of treating mood disorders?
Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of depressive and bipolar disorder patients with mixed features.
Tondo L; Vázquez GH; Pinna M; Vaccotto PA; Baldessarini RJ
Acta Psychiatr Scand; 2018 Sep; 138(3):243-252. PubMed ID: 29862493
[TBL] [Abstract][Full Text] [Related]
17. [Treatment-resistant mood disorders].
Machado-Vieira R; Soares JC
Braz J Psychiatry; 2007 Oct; 29 Suppl 2():S48-54. PubMed ID: 17713691
[TBL] [Abstract][Full Text] [Related]
18. Mixed features in major depressive disorder: diagnoses and treatments.
Suppes T; Ostacher M
CNS Spectr; 2017 Apr; 22(2):155-160. PubMed ID: 28462772
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis.
Bond DJ; Noronha MM; Kauer-Sant'Anna M; Lam RW; Yatham LN
J Clin Psychiatry; 2008 Oct; 69(10):1589-601. PubMed ID: 19192442
[TBL] [Abstract][Full Text] [Related]
20. Coding and noncoding gene expression biomarkers in mood disorders and schizophrenia.
Mamdani F; Martin MV; Lencz T; Rollins B; Robinson DG; Moon EA; Malhotra AK; Vawter MP
Dis Markers; 2013; 35(1):11-21. PubMed ID: 24167345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
